Since 2024, Mellon Medical has been part of the Demcon group. The company has developed a groundbreaking suture instrument that allows a surgeon to suture with only one hand. This innovation makes surgical suturing faster, more precise and more efficient, offering significant benefits to both physicians and patients.

Bond3D develops advanced 3D printing technology for producing functional components from high-performance plastics. Applications include medical implants and complex components for high-tech systems. Since its acquisition by the Demcon group in 2024, Bond3D has greater financial clout and extensive R&D and engineering capabilities. This accelerates the development of new, high-value applications in 3D printed plastic products.

Orgonex has developed an innovative bioreactor for growing organoids: miniature organs essential for medical, biotechnology and pharmaceutical research. The bioreactor provides five times the yield of traditional manual methods and is more compact and user-friendly than existing automatic solutions. Within the Demcon group, this system is now being further developed into a professional product, to be launched on the market before the end of this year.

FSO, a 50-50 Joint Venture between Demcon and VDL, develops systems for the fast-growing market for optical communications in and to space. In early 2024, CubeCAT, a terminal using the technology, reached a milestone with a successful “In Orbit” validation on satellite NORSAT TD: the world's fastest 1U-sized laser terminal (10x10x10cm) has established regular stable connections with multiple ground stations over the past year. A major step toward ultra-fast, secure data communications via space that FSO is now building on to a complete portfolio of dual-use communications solutions.

In December 2022, Demcon investment together with a large number of Dutch investors invested in the Bioneedle Drug Delivery startup in Leiden. Bioneedle Drug Delivery has put a new production line into operation for the production of bio-needles for an injection system that makes vaccination simpler, faster and safer. These bio-needles shoot a dry vaccine painlessly under the skin, where it subsequently rapidly dissolves. This eliminates the need for cooling vaccines, which makes it possible to distribute vaccines throughout the world faster and more economically. The line has been built at Demcon in Enschede. Demcon acts as a development and production partner for the innovative Bioneedle technology. 
Read more

One of the companies in Demcon investment’s portfolio is the Dutch MedTech company LiGalli. Together with Demcon teams in Delft and Best, LiGalli is rapidly developing the new innovative LiGalli MedRing. This is a unique vaginal ring that delivers medication in liquid form against incontinence in a controlled way. A smartphone is used to control the MedRing. The LiGalli MedRing makes it possible to more effectively deliver medication through the vaginal canal and improves diagnostics. This makes it possible to more specifically treat incontinence, as a result of which women no longer need to experience any limitations in their social activities. There are more than 100 rings under development, all of which are first generation. The first application is focused on countering incontinence. The partners are now working on new versions of the MedRing for the delivery of other medications, and on better diagnostics and opportunities for mass production.
Read more